Shamburg News · 8-K filed Nov 13, 2026, 4:35 PM EST

Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

CLDI · Calidi Biotherapeutics, Inc.

  • Earnings
  • Other event
  • Materiality: high

Calidi Biotherapeutics, Inc. reported a net loss attributable to common stockholders of $3.6 million for the third quarter of 2026, compared with $10.8 million for the third quarter of 2025, which included a $5.7 million non-cash deemed dividend on warrants. Research and development expenses were $2.7 million and general and administrative expenses were $1.6 million for the quarter. The company received $1.2 million in gross proceeds from an at-the-market registered direct offering that closed September 18, 2026, and executed a restructuring plan on November 6, 2026, expected to save $3 million annualized. Cash was $3.9 million as of September 30, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001193125-26-460816.

Written from the filing by Shamburg Markets. Figures are as reported by the company.